Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Diabetes and Vascular Disease Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Walcher, D.
Right arrow Articles by Marx, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walcher, D.
Right arrow Articles by Marx, N.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Insulin resistance and cardiovascular disease: the role of PPAR{gamma} activators beyond their anti-diabetic action

Daniel Walcher

University of Ulm, Robert-Koch-Str. 8, D-89081 Ulm, Germany

Nikolaus Marx

University of Ulm, Robert-Koch-Str. 8, D-89081 Ulm, Germany

Over the past few years it has been recognised that insulin resistance (IR) is an independent risk factor for major cardiovascular events. In addition, IR is associated with other factors such as hypertension, dyslipidaemia and endothelial dysfunction, and this cluster of metabolic disorders contributes to the cardiovascular risk of patients with IR. Given the increasing number of patients with IR, the modulation of their cardiovascular risk is a major task in diabetology and vascular medicine. This review will focus on the role of IR as a cardiovascular risk factor and on the potential of activators of the nuclear transcription factor peroxisome proliferator-activated receptor gamma (PPAR{gamma}) to modulate these risk factors associated with IR.

Key Words: insulin resistance • PPAR{gamma} • activators • thiazolidinediones • cardiovascular risk

References

  • 1. Pyorala M, Miettinen H, Halonen P, Laakso M, Pyorala K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study . Arterioscler Thromb Vasc Biol 2000;20:538–44.[Abstract/Free Full Text]
  • 2. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome . Diabetes Care 2001;24:683–9.[Abstract/Free Full Text]
  • 3. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study . Diabetes Care 2002;25:1177–84.[Abstract/Free Full Text]
  • 4. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management . JAMA 2002;287:2570–81.[Abstract/Free Full Text]
  • 5. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic induviduals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? . JAMA 1990;263:2893–8.[Abstract/Free Full Text]
  • 6. Hsueh WA, Law RE. Cardiovascular risk continuum: implications of insulin resistance and diabetes . Am J Med 1998;105:4S–14S.[CrossRef][Medline] [Order article via Infotrieve]
  • 7. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events . Thromb Haemost 1997;78:656–60.[Web of Science][Medline] [Order article via Infotrieve]
  • 8. Reaven GM. Banting Lecture: role of insulin resistance in human disease . Diabetes 1988;37:1595–607.[Abstract]
  • 9. National Cholesterol Education Program NCEP Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report . Circulation 2002;106:3143–421.[Free Full Text]
  • 10. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells . Circ Res 2004;94:1168–78.[Abstract/Free Full Text]
  • 11. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta . Proc Natl Acad Sci USA 1997;94:4312–17.[Abstract/Free Full Text]
  • 12. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism . Circulation 1998;98:2088–93.[Abstract/Free Full Text]
  • 13. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor . Diabetes 1998;47:507–14.[Abstract]
  • 14. Kim JB, Spiegelman BM. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism . Genes Dev 1996;10:1096–107.[Abstract/Free Full Text]
  • 15. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor . Cell 1994;79:1147–56.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 16. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation . Cell 1995;83:813–19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 17. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma . Cell 1998;93:229–40.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 18. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL . Cell 1998;93:241–52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 19. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) . J Biol Chem 1995;270:12953–6.[Abstract/Free Full Text]
  • 20. Finegood DT, McArthur MD, Kojwang D et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death . Diabetes 2001;50:1021–9.[Abstract/Free Full Text]
  • 21. Festa A, D'Agostino R Jr, Mykkanen L, Tracy R, Howard BV, Haffner SM. Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study . Arterioscler Thromb Vasc Biol 1999;19:605–10.[Abstract/Free Full Text]
  • 22. Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis . J Cardiovasc Risk 2000;7:325–31.[Web of Science][Medline] [Order article via Infotrieve]
  • 23. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition . Circulation 2004;109:433–8.[Free Full Text]
  • 24. Winkler K, Konrad T, Fullert S et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study . Diabetes Care 2003;26:2588–94.[Abstract/Free Full Text]
  • 25. Sakamoto J, Kimura H, Moriyama S et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone . Biochem Biophys Res Commun 2000;278:704–11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 26. Martin G, Schoonjans K, Staels B, Auwerx J. PPARgamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes . Atherosclerosis 1998;137(suppl):S75–S80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 27. Fullert S, Schneider F, Haak E et al. Effects of pioglitazone in non-diabetic patients with arterial hypertension: a double-blind, placebo-controlled study . J Clin Endocrinol Metab 2002;87:5503–06.[Abstract]
  • 28. Hirose H, Hayashi K, Saito I, Saruta K. Insulin resistance and hypertension: seven-year follow-up study in Japanese men . Diabetes 2002;51:(suppl 2): 926-P (abstract).
  • 29. Song J, Walsh MF, Igwe R et al. Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production . Diabetes 1997;46:659–64.[Abstract]
  • 30. Kawasaki J, Hirano K, Nishimura J, Fujishima M, Kanaide H. Mechanisms of vasorelaxation induced by troglitazone, a novel antidiabetic drug, in the porcine coronary artery . Circulation 1998;98:2446–52.[Abstract/Free Full Text]
  • 31. Satoh H, Tsukamoto K, Hashimoto Y et al. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function . Biochem Biophys Res Commun 1999;254:757–63.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 32. Honisett SY, Stojanovska L, Sudhir K, Kingwell BA, Dawood T, Komesaroff P. Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes . Diabetes Care 2003;26:3194–5.[Free Full Text]
  • 33. Stoney RM, O'Dea K, Herbert KE et al. Insulin resistance as a major determinant of increased coronary heart disease risk in postmenopausal women with type 2 diabetes mellitus . Diabet Med 2001;18:476–82.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 34. Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence . Circulation 1998;97:2213–21.[Abstract/Free Full Text]
  • 35. Koenig W. Haemostatic risk factors for cardiovascular diseases . Eur Heart J 1998;19(suppl C):C39–C43.[Web of Science][Medline] [Order article via Infotrieve]
  • 36. Festa A, D'Agostino R Jr, Mykkanen L et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS) . Arterioscler Thromb Vasc Biol 1999;19:562–8.[Abstract/Free Full Text]
  • 37. Fonseca VA, Reynolds T, Hemphill D et al. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus . J Diabetes Complications 1998;12:181–6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 38. Sidhu JS, Cowan D, Tooze JA, Kaski JC. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease . Am Heart J 2004;147: e25 .[Medline] [Order article via Infotrieve]
  • 39. Burke AP, Kolodgie FD, Zieske A et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study . Arterioscler Thromb Vasc Biol 2004;24:1266–71.[Abstract/Free Full Text]
  • 40. Ross R. Atherosclerosis-an inflammatory disease . N Engl J Med 1999;340:115–26.[Free Full Text]
  • 41. Marx N, Walcher D, Raichle C et al. C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro . Arterioscler Thromb Vasc Biol 2004;24:540–5.[Abstract/Free Full Text]
  • 42. Walcher D, Aleksic M, Jerg V et al. C-peptide induces chemotaxis of human CD4-positive cells — involvement of pertussis toxin-sensitive G-proteins and PI 3-kinase . Diabetes 2004;53:1664–70.[Abstract/Free Full Text]
  • 43. Kuvin JT, Karas RH. Clinical utility of endothelial function testing: ready for prime time? . Circulation 2003;107:3243–7.[Free Full Text]
  • 44. Balletshofer BM, Rittig K, Enderle MD et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance . Circulation 2000;101:1780–4.[Abstract/Free Full Text]
  • 45. Balletshofer B, Rittig K, Stock J et al. Insulin resistant young subjects at risk of accelerated atherosclerosis exhibit a marked reduction in peripheral endothelial function early in life but not differences in intima-media thickness . Atherosclerosis 2003;171:303–09.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 46. Marx N. Peroxisome proliferator-activated receptor gamma and atherosclerosis . Curr Hypertens Rep 2002;4:71–7.[Web of Science][Medline] [Order article via Infotrieve]
  • 47. Jackson SM, Parhami F, Xi XP et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction . Arterioscler Thromb Vasc Biol 1999;19:2094–104.[Abstract/Free Full Text]
  • 48. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators . Circulation 2000;101:235–8.[Abstract/Free Full Text]
  • 49. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines . Nature 1998;391:82–6.[CrossRef][Medline] [Order article via Infotrieve]
  • 50. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation . Nature 1998;391:79–82.[CrossRef][Medline] [Order article via Infotrieve]
  • 51. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro . Am J Pathol 1998;153:17–23.[Abstract/Free Full Text]
  • 52. Marx N, Schönbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells . Circ Res 1998;83:1097–103.[Abstract/Free Full Text]
  • 53. Collins AR, Meehan WP, Kintscher U et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice . Arterioscler Thromb Vasc Biol 2001;21:365–71.[Abstract/Free Full Text]
  • 54. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice . J Clin Invest 2000;106:523–31.[Web of Science][Medline] [Order article via Infotrieve]
  • 55. Caballero AE, Saouaf R, Lim SC et al. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial . Metabolism 2003;52:173–80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 56. Sidhu JS, Cowan D, Kaski JC. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus . Am J Cardiol 2004;64:151–6.
  • 57. Cominacini L, Garbin U, Fratta Pasini A et al. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients . Diabetes 1998;47:130–3.[Abstract]
  • 58. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey . Lancet 1988;2:530–3.[Web of Science][Medline] [Order article via Infotrieve]
  • 59. Agewall S, Wikstrand J, Ljungman S, Fagerberg B. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk Factor Intervention Study Group . Am J Cardiol 1997;80:164–9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 60. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes . J Hum Hypertens 2003;17:7–12.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 61. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes . J Clin Endocrinol Metab 1998;83:1818–20.[Abstract/Free Full Text]
  • 62. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus . Arterioscler Thromb Vasc Biol 2004;24:930–4.[Abstract/Free Full Text]
  • 63. Ridker PM, Hennekens CH, Roitman Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men . Lancet 1998;351:88–92.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 64. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women . N Engl J Med 2000;342:836–43.[Abstract/Free Full Text]
  • 65. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men . Circulation 2000;101:1767–72.[Abstract/Free Full Text]
  • 66. Ridker P, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction . Circulation 2000;101:2149–53.[Abstract/Free Full Text]
  • 67. Koenig W, Sund M, Frohlich M et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992 . Circulation 1999;99:237–42.[Abstract/Free Full Text]
  • 68. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS) . Circulation 2000;102:42–7.[Abstract/Free Full Text]
  • 69. Koenig W. Insulin resistance, heart disease and inflammation. Identifying the ‘at-risk’ patient: the earlier the better? The role of inflammatory markers . Int J Clin Pract 2002;132(suppl):23–30.
  • 70. Aldhahi W, Hamdy O. Adipokines, inflammation, and the endothelium in diabetes . Curr Diab Rep 2003;3:293–8.[Medline] [Order article via Infotrieve]
  • 71. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus . Circulation 2002;106:679–84.[Abstract/Free Full Text]
  • 72. Marx N, Froehlich J, Siam L et al. Effect of rosiglitazone treatment on soluble CD40L in type-2 diabetic patients with coronary artery disease . Circulation 2003;107:1954–7.[Abstract/Free Full Text]
  • 73. Marx N, Froehlich J, Siam L et al. The antidiabetic PPARg-activator rosiglitazone reduces MMP-9 serum levels in type-2 diabetic patients with coronary artery disease . Arterioscler Thromb Vasc Biol 2003;23:283–8.[Abstract/Free Full Text]
  • 74. Takagi T, Akasaka T, Yamamuro A et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study . J Am Coll Cardiol 2000;36:1529–35.[Abstract/Free Full Text]
  • 75. Osman A, Otero J, Brizolara A et al. Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes . Am Heart J 2004;147: e23 .[CrossRef][Medline] [Order article via Infotrieve]
  • 76. Barman-Balfour JA, Plosker GL. Rosiglitazone . Drugs 1999;57:921–30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 77. Thomas ML, Lloyd SJ. Pulmonary edema associated with rosiglitazone and troglitazone . Ann Pharmacother 2001;35:123–4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 78. Niemeyer NV, Janney LM. Thiazolidinedione-induced edema . Pharmacotherapy 2002;22:924–9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 79. Wooltorton E. Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure . Cmaj 2002;166: 219 .[Free Full Text]
  • 80. Tang WH, Francis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure . J Am Coll Cardiol 2003;41:1394–8.[Abstract/Free Full Text]

Diabetes and Vascular Disease Research, Vol. 1, No. 2, 76-81 (2004)
DOI: 10.3132/dvdr.2004.011
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
F. Desjardins, B. Sekkali, W. Verreth, M. Pelat, D. De Keyzer, A. Mertens, G. Smith, M.-C. Herregods, P. Holvoet, and J.-L. Balligand
Rosuvastatin increases vascular endothelial PPAR{gamma} expression and corrects blood pressure variability in obese dyslipidaemic mice
Eur. Heart J., January 1, 2008; 29(1): 128 - 137.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Walcher, D.
Right arrow Articles by Marx, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walcher, D.
Right arrow Articles by Marx, N.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?